Cargando…

5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia

SIMPLE SUMMARY: Leukemic growth results in selective silencing of gene transcripts involved in immune detection, differentiation, and apoptosis. Hypomethylating agents (HMAs), such as 5-azacytidine, have been shown to reprogram the genetic landscape in various cancers to restore both transgene and e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebelt, Nancy D., Manuel, Edwin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817798/ https://www.ncbi.nlm.nih.gov/pubmed/36612115 http://dx.doi.org/10.3390/cancers15010118

Ejemplares similares

5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma
por: Ebelt, Nancy D., et al.
Publicado: (2020)

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
por: Tibes, Raoul, et al.
Publicado: (2015)

The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
por: Alrajhi, Abdullah M., et al.
Publicado: (2019)

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
por: Aumer, Tina, et al.
Publicado: (2022)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Redirecting the Immune Microenvironment in Acute Myeloid Leukemia
por: Sendker, Stephanie, et al.
Publicado: (2021)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

Transcriptomic Profiles of MV4-11 and Kasumi 1 Acute Myeloid Leukemia Cell Lines Modulated by Epigenetic Modifiers Trichostatin A and 5-Azacytidine
por: Asmaa, Mat Jusoh Siti, et al.
Publicado: (2020)

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia
por: Wang, Yanyu, et al.
Publicado: (2022)

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
por: Klosner, Justine, et al.
Publicado: (2021)

Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: Wang, Wei, et al.
Publicado: (2022)

5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies
por: Gang, A O, et al.
Publicado: (2014)

Modulation of Cell Cycle Progression by 5-Azacytidine Is Associated with Early Myogenesis Induction in Murine Myoblasts
por: Montesano, Anna, et al.
Publicado: (2013)

Retracted: Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine
por: Cabezón, Marta, et al.
Publicado: (2018)

Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
por: Rohon, Peter, et al.
Publicado: (2012)

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
por: Xu, Ning, et al.
Publicado: (2021)

Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
por: Chau, David, et al.
Publicado: (2015)

Retracted: Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
por: Berthon, Celine, et al.
Publicado: (2020)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.
por: Greco, M., et al.
Publicado: (2011)

Synthesis and Antiproliferative Activities of 5-Azacytidine Analogues in Human Leukemia Cells
por: Guo, Gang, et al.
Publicado: (2008)

Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity
por: Lamble, Adam J., et al.
Publicado: (2018)

Murine Models of Acute Myeloid Leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2022)

Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review
por: Katagiri, Takayuki, et al.
Publicado: (2017)

5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity
por: Stübig, Thomas, et al.
Publicado: (2014)

Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol
por: Šimoničová, Kristína, et al.
Publicado: (2023)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment
por: Guo, Rongqun, et al.
Publicado: (2021)

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
por: Bogenberger, J M, et al.
Publicado: (2014)

Corrigendum: Murine models of acute myeloid leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2023)

Comment on “5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity”
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Identification of prognostic genes in the acute myeloid leukemia microenvironment
por: Huang, Shaoxin, et al.
Publicado: (2019)

Tumor Microenvironment in Acute Myeloid Leukemia: Adjusting Niches
por: Menter, Thomas, et al.
Publicado: (2022)

The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
por: Pimenta, Débora Bifano, et al.
Publicado: (2021)

Targeted Depletion of Hyaluronic Acid Mitigates Murine Breast Cancer Growth
por: Zamloot, Vic, et al.
Publicado: (2022)

Molecular Systems Architecture of Interactome in the Acute Myeloid Leukemia Microenvironment
por: Ayyadurai, V. A. Shiva, et al.
Publicado: (2022)

The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia
por: Xu, Binyan, et al.
Publicado: (2022)

5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion
por: Bhuvanagiri, Madhuri, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4vupqk9cfbnmkdo8vjtvl4a4l4